4basebio (LSE:4BB) Capex-to-Revenue : 3.09 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

4basebio's Capital Expenditure for the six months ended in Jun. 2023 was £-0.74 Mil. Its Revenue for the six months ended in Jun. 2023 was £0.24 Mil.

Hence, 4basebio's Capex-to-Revenue for the six months ended in Jun. 2023 was 3.09.

4basebio Capex-to-Revenue Historical Data

The historical data trend for 4basebio's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Capex-to-Revenue Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Capex-to-Revenue

1.01

1.84

4.47

7.24

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Capex-to-Revenue	Get a 7-Day Free Trial			2.08	7.17	9.03	4.90	3.09

Competitive Comparison of 4basebio's Capex-to-Revenue

For the Biotechnology subindustry, 4basebio's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where 4basebio's Capex-to-Revenue falls into.

4basebio Capex-to-Revenue Calculation

4basebio's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-1.941)	/	0.268
	=	7.24

4basebio's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.736)	/	0.238
	=	3.09

4basebio (LSE:4BB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

4basebio Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of 4basebio's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (LSE:4BB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

88Q:Germany

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (LSE:4BB) Headlines

No Headlines